Journal
JOURNAL OF ALZHEIMERS DISEASE
Volume 67, Issue 2, Pages 481-488Publisher
IOS PRESS
DOI: 10.3233/JAD-180325
Keywords
Alzheimer's disease; astrocyte; biomarker; cerebrospinal fluid; differential diagnosis; frontotemporal dementia; GFAP; Lewy body dementia; Parkinson's disease; serum
Categories
Funding
- JPND network SOPHIA [01ED1202A]
- German Federal Ministry of Education and Research [FTLDc 01GI1007A, MND-Net 01GM1103A]
- EU [NADINE 246513, FAIR-PARK II 633190]
- German Research Foundation/DFG [SFB1279]
- foundation of the state Baden-Wurttemberg [D.3830]
- Boehringer Ingelheim Ulm University Bio-Center [D.5009]
- Thierry Latran Foundation
- Innovative Medicines Initiative Joint Undertaking under EMIF from the European Union's Seventh Framework Programme (FP7/2007-2013) [115372]
- EFPIA companies
- JPND network BiomarkAPD [01ED1203F]
- JPND network PreFrontAls [01ED1512]
Ask authors/readers for more resources
Reliable blood biomarkers for Alzheimer's disease (AD) are missing. We measured astroglial GFAP in patients with AD (n = 28), frontotemporal dementia (bvFTD, n = 35), Parkinson's disease (n = 11), Lewy body dementias (n = 19), and controls (n = 34). Serum GFAP was increased in AD (p < 0.001) and DLB/PDD (p < 0.01), and cerebrospinal fluid GFAP was increased in all neurodegenerative diseases (p < 0.001). Serum GFAP correlated with the Mini-Mental State Examination score (r = -0.42, p < 0.001) and might be a follow-up marker in clinical trials. Sensitivity and specificity of serum GFAP for AD versus bvFTD was 89% and 79% and might be the first blood biomarker in the differential diagnosis of AD and bvFTD.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
